Navigation Links
AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:10/1/2008

H

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment completion was announced today, involves approximately 400 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment started in May 2008, is an ongoing open-label, single-armed study involving approximately 500 patients in both North America and Europe.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
2. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
3. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
4. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
5. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
6. AEterna Zentaris Sells Quebec City Building for $7.1 million
7. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
8. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
9. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
10. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
11. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Rhythm, a biopharmaceutical company developing peptide ... result in metabolic disorders, announced today that it has ... U.S. Securities and Exchange Commission (SEC) relating to the ... stock. The number of shares to be offered and ... been determined. Citigroup and Cowen and Company ...
(Date:8/27/2014)... --  MSC , a healthcare performance improvement company advancing ... of Mary Beth Loesch to President and ... preparing companies for rapid growth and market expansion, Loesch ... Corporate Development and Healthcare. In that role, she oversaw ... as corporate strategy and marketing. Previously, Loesch served as ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent ... can form covalent bonds with metal ions, thereby ... effect that some metal-ions have on chemical processes, ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4
... Jolla, Calif. -- Stratagene Corp. will appeal the jury ... company last week. , ,Stratagene on Saturday announced its move ... United States District Court for the Western District of Wisconsin. ... damages. , ,Stratagene said in a news release that it ...
... mantra for student technology usage on campus, according to ... to surpass desktop computers and an expanding interest in ... Survey, which randomly polled 1,600 students last spring, looked ... future areas of need. The survey is sponsored by ...
... Madison professor emeritus Larry Landweber, who was involved in one ... his expertise on the next stage of the Internet, which ... Computer & Information Science & Engineering (CISE) branch ... research project that may lead to the next generation of ...
Cached Biology Technology:Stratagene to appeal verdict won by Third Wave 2Student survey shows surging demand for wireless access 2Madison professor emeritus will consult on development of 'Internet 2' 2Madison professor emeritus will consult on development of 'Internet 2' 3
(Date:8/28/2014)... Munich have assigned a number of 435-million-year-old fossils ... animals lived in shallow marine habitats and were ... Jurassic strata. , Before they sank to ... were fossilized some 435 million years ago, these ... seas although they were not exactly inconspicuous, ...
(Date:8/27/2014)... bears, giant ground sloths, saber-toothed cats and American camels ... at the end of the Pleistocene period. The cause ... scientists who, until recently, could only speculate as to ... Barbara,s James Kennett, professor emeritus in the Department of ... played a major role in the extinction. Their hypothesis ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3Water 'thermostat' could help engineer drought-resistant crops 2
... satellite data and climate models have projected drier conditions ... States in coming decades. Other findings about U.S. wildfires, ... length and strength of fire seasons are expected to ... at the annual meeting of the American Geophysical Union ...
... T.J. Tabasco, a pig from the University of Illinois South ... by an international consortium. It is expected to speed progress ... President for Research Lawrence Schook said that the College of ... Funding that came through ACES allowed Schook and others ...
... 4, 2012 - The 2010 blowout of the Macondo well ... the region,s largest oil spill in U.S. history. As the ... the oil from coming to the surface and reaching coastal ... These powerful dispersants, typically used to break up oil slicks ...
Cached Biology News:Climate models project increase in US wildfire risk 2Climate models project increase in US wildfire risk 3Hogging the spotlight: South Farms pig gets international attention 2Numerical study suggests subsea injection of chemicals didn't prevent oil from rising to sea surface 2Numerical study suggests subsea injection of chemicals didn't prevent oil from rising to sea surface 3
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... A modified nucleotide structure called ... 5?-end of most naturally-occurring eukaryotic mRNAs ... Cap Analog for a portion of ... vitro transcription reaction results in the ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... Refrigerated Console Orbital Shakers combine high ... unequalled programming power. The patented ... the unit to run with heavy ... filtration system reduces contamination. The ...
Biology Products: